AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6287928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal enviroxime
Number of subjects: 40
Study 31237727 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg risankizumab
Number of subjects: 171
Study 31237727 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg risankizumab
Number of subjects: 171
Study 31237727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 29562156 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab
Number of subjects: 389
Study 29562156 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab
Number of subjects: 389
Study 29562156 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (in patients with chromosome 17p deletion)
Number of subjects: 389
Study 29562156 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (in patients with chromosome 17p deletion)
Number of subjects: 389
Study 29562156 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (in patients without chromosome 17p deletion)
Number of subjects: 389
Study 29562156 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (in patients without chromosome 17p deletion)
Number of subjects: 389
Study 26171754 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultation during monthly home visits
Number of subjects: 188
Study 26171754 — intervention group
Group type: COMPARATOR
Intervention: Regular monthly home visits (no video consultation)
Number of subjects: 188
Study 24881178 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing of two catheters by continence nurses.
Number of subjects: 16
Study 22304676 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) bibliotherapy
Number of subjects: 26
Study 22304676 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 26
Study 22304676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (post-treatment and 1-month follow-up)
Number of subjects: 26
Study 22304676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (1-month follow-up)
Number of subjects: 26
Study 20467191 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and resistance exercise programs for 3 months)
Number of subjects: 38
Study 20467191 — intervention group
Group type: COMPARATOR
Intervention: Control group without exercise training
Number of subjects: 38
Study 17591303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IV cannulation
Number of subjects: 35
Study 17591303 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of IV cannulation
Number of subjects: 35
Study 16228157 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 200
Study 16228157 — intervention group
Group type: COMPARATOR
Intervention: Gravity drainage
Number of subjects: 200
Study 12365197 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 12
Study 12365197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 120 mg
Number of subjects: 12
Study 10421239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg four times daily)
Number of subjects: 14
Study 10421239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7472685 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with positive attitudes toward psychosocial aspects of care
Number of subjects: 473
Study 7472685 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients of physicians with positive attitudes
Number of subjects: 473
Study 2264198 — intervention group
Group type: COMPARATOR
Intervention: No additional therapeutic measures (Group 1)
Number of subjects: 89
Study 2264198 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with the BCG vaccine (Group 2)
Number of subjects: 89
Study 2264198 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole for immunotherapy (Group 3)
Number of subjects: 89
Study 2264198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method: BCG vaccine, placental suspension, and cyclophosphamide (Group 4)
Number of subjects: 89
Study 7406204 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL (Halothane)
Number of subjects: 0
Study 7406204 — intervention group
Group type: EXPERIMENTAL
Intervention: NAL (Nitrous Oxide)
Number of subjects: 0
Study 7406204 — intervention group
Group type: COMPARATOR
Intervention: EHA (Enflurane)
Number of subjects: 0
Study 29952829 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 102
Study 29952829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 28869573 — intervention group
Group type: EXPERIMENTAL
Intervention: LEU (L-leucine)
Number of subjects: 75
Study 28869573 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Concentrate (WPC)
Number of subjects: 75
Study 28869573 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (WPH)
Number of subjects: 75
Study 28869573 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy Protein Concentrate (SPC)
Number of subjects: 75
Study 28869573 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin Placebo (PLA)
Number of subjects: 75
Study 26187233 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR) - 25% reduction in caloric intake
Number of subjects: 218
Study 26187233 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AL) diet
Number of subjects: 218
Study 23573255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberball-induced exclusion (SE)
Number of subjects: 43
Study 23573255 — intervention group
Group type: COMPARATOR
Intervention: Cyberball-induced inclusion (SI)
Number of subjects: 43
Study 21365629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lonafarnib (LNF) and Docetaxel (DTX)
Number of subjects: 38
Study 17522596 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (5-20 cm2)
Number of subjects: 0
Study 17522596 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine capsules (1.5-6 mg Q12H, i.e., 3-12 mg/day)
Number of subjects: 0
Study 16440148 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administered intravenously during the operation
Number of subjects: 20
Study 16440148 — intervention group
Group type: COMPARATOR
Intervention: Routine CABG protocol (Control group)
Number of subjects: 20
Study 12691318 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm)
Number of subjects: 192
Study 12691318 — intervention group
Group type: COMPARATOR
Intervention: conventional surgery or radiotherapy alone (CO arm)
Number of subjects: 192
Study 10891820 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1 mg/m²/d) for 24 months
Number of subjects: 35
Study 8979288 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate, 200 micrograms
Number of subjects: 17
Study 8979288 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 400 micrograms
Number of subjects: 17
Study 8979288 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 800 micrograms
Number of subjects: 17
Study 8102222 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic vecuronium
Number of subjects: 10
Study 8102222 — intervention group
Group type: COMPARATOR
Intervention: Isolated forearm vecuronium
Number of subjects: 10
Study 8102222 — intervention group
Group type: COMPARATOR
Intervention: Nonisolated arm vecuronium
Number of subjects: 10
Study 8102222 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated systemic vecuronium
Number of subjects: 10
Study 3519883 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard (L-PAM)
Number of subjects: 0
Study 31751466 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg L-DOPA
Number of subjects: 54
Study 31751466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29664406 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 302
Study 29664406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 28381428 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 39
Study 28381428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and radiotherapy (RT)
Number of subjects: 40
Study 26088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and RT
Number of subjects: 40
Study 26088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and RT in codeleted patients
Number of subjects: 40
Study 26088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and RT in non-codeleted patients
Number of subjects: 40
Study 26088460 — intervention group
Group type: COMPARATOR
Intervention: Comparison with codeleted procarbazine/CCNU/vincristine (PCV) and RT cohort in RTOG 9402
Number of subjects: 40
Study 23017467 — intervention group
Group type: EXPERIMENTAL
Intervention: Food addiction symptomology
Number of subjects: 57
Study 20226502 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan (Iri) 35 mg/m(2) and cisplatin (CP) 20 mg/m(2) with 45‐Gy pelvic irradiation
Number of subjects: 15
Study 19213341 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medical treatment plus prednisone
Number of subjects: 110
Study 19213341 — intervention group
Group type: COMPARATOR
Intervention: Prednisone only (control group)
Number of subjects: 110
Study 16860509 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plasma concentration monitoring
Number of subjects: 58
Study 16860509 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosage and concentration correlation with INR
Number of subjects: 58
Study 12673147 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to the lower leg muscles
Number of subjects: 20
Study 12673147 — intervention group
Group type: COMPARATOR
Intervention: No NMES (motionless standing)
Number of subjects: 20
Study 10816062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 37
Study 10816062 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctr)
Number of subjects: 37
Study 8800634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 923
Study 8800634 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 923
Study 8800634 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more AEDs
Number of subjects: 923
Study 8800634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin and one other AED
Number of subjects: 923
Study 1457271 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 1457271 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 6319449 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg bolus followed by 5 micrograms/kg/h infusion)
Number of subjects: 8
Study 6319449 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 8
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic alterations (copy-number aberrations and copy-neutral loss of heterozygosity) identified by chromosome genomic-array testing (CGAT) at FL diagnosis
Number of subjects: 255
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: 2p gain
Number of subjects: 255
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: 2p cnLOH
Number of subjects: 255
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: 2p gain encompassing VRK2 and FANCL
Number of subjects: 255
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A/B (9p) deletion
Number of subjects: 255
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: CREBBP (16p) deletion
Number of subjects: 255
Study 30446494 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 (17p) deletion
Number of subjects: 255
Study 29940217 — intervention group
Group type: EXPERIMENTAL
Intervention: BNX-RDT 11.4/2.9 mg
Number of subjects: 125
Study 29940217 — intervention group
Group type: EXPERIMENTAL
Intervention: BNX-RDT 2.9/0.71 mg
Number of subjects: 125
Study 29940217 — intervention group
Group type: EXPERIMENTAL
Intervention: BNX-RDT
Number of subjects: 125
Study 27050599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective group (CAO/ARO/AIO-04 trial)
Number of subjects: 479
Study 27050599 — intervention group
Group type: COMPARATOR
Intervention: CAO/ARO/AIO-94 cohort
Number of subjects: 479
Study 24387594 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care ethics consultation (HCEC)
Number of subjects: 62
Study 24387594 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 62
Study 21962726 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment (BT)
Number of subjects: 378
Study 20157652 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia 21 (P21)
Number of subjects: 96
Study 20157652 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Bond C&B (SB)
Number of subjects: 96
Study 20157652 — intervention group
Group type: COMPARATOR
Intervention: Chemiace II (CH)
Number of subjects: 96
Study 20157652 — intervention group
Group type: EXPERIMENTAL
Intervention: Roughened dentinal walls (all cements)
Number of subjects: 96
Study 20157652 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage for 150 days with thermal cycling and mechanical loading
Number of subjects: 96
Study 17658977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of physical punishment
Number of subjects: 120
Study 17658977 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of child-reported parental warmth and involvement
Number of subjects: 120
Study 17658977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of anxiety
Number of subjects: 120
Study 16125499 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan or enalapril or both (specific dosages and duration not mentioned)
Number of subjects: 768
Study 11831838 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg once daily
Number of subjects: 15
Study 10399370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate
Number of subjects: 18
Study 10399370 — intervention group
Group type: COMPARATOR
Intervention: Guanosine 5'-monophosphate
Number of subjects: 18
Study 10399370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 18
Study 7494939 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study 7494939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 1553897 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: metoclopramide [2 mg/kg x 4 i.v.] + methylprednisolone (250 mg x 2 i.v.) + diphenhydramine (50 mg x 2 i.v.)
Number of subjects: 32
Study 1553897 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: metoclopramide (3 mg/kg x 2 i.v.) + dexamethasone (20 mg i.v.) + diphenhydramine (50 mg i.v.)
Number of subjects: 32
Study 3898413 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 55
Study 3898413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31126825 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART intervention (8-week program)
Number of subjects: 102
Study 31126825 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL) followed by SMART intervention
Number of subjects: 102
Study 29587875 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlife® CRADLE Vital Sign Alert (VSA) device and CRADLE training package
Number of subjects: 10
Study 29587875 — intervention group
Group type: COMPARATOR
Intervention: Routine maternity care
Number of subjects: 10
Study 30230756 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Candesartan
Number of subjects: 75
Study 30230756 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 75
Study 30230756 — intervention group
Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 75
Study 25528622 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed locked intramedullary nailing
Number of subjects: 68
Study 25528622 — intervention group
Group type: COMPARATOR
Intervention: Biplanar external fixation
Number of subjects: 68
Study 25528622 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using SF-36 Health Survey
Number of subjects: 68
Study 22647889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined simvastatin and ezetimibe treatment
Number of subjects: 1616
Study 22647889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1616
Study 20501862 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (30 mg/d for 3 years)
Number of subjects: 1166
Study 20501862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1166
Study 18344886 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 10
Study 18344886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18344886 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 10
Study 18344886 — intervention group
Group type: COMPARATOR
Intervention: Infliximab and Placebo
Number of subjects: 10
Study 16538734 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 6 +/- 2 mg/kg
Number of subjects: 1099
Study 16538734 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 15 +/- 2 mg/kg
Number of subjects: 1099
Study 16538734 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 24 +/- 2 mg/kg
Number of subjects: 1099
Study 16538734 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 34 +/- 2 mg/kg
Number of subjects: 1099
Study 12434280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/epinephrine gel
Number of subjects: 92
Study 12434280 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 92
Study 9580075 — intervention group
Group type: EXPERIMENTAL
Intervention: Butantan polyspecific, pepsin‐digested Bothrops antivenom (Group A)
Number of subjects: 79
Study 9580075 — intervention group
Group type: EXPERIMENTAL
Intervention: Butantan polyspecific, whole IgG Bothrops antivenom (Group B)
Number of subjects: 79
Study 9580075 — intervention group
Group type: EXPERIMENTAL
Intervention: Colombian commercial, monovalent, whole IgG Bothrops antivenom (Group C)
Number of subjects: 79
Study 9580075 — intervention group
Group type: COMPARATOR
Intervention: All antivenoms
Number of subjects: 79
Study 7822630 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based tic assessment procedure (direct observations, teacher rating scales)
Number of subjects: 0
Study 7822630 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observations of tics
Number of subjects: 0
Study 7822630 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher rating scales
Number of subjects: 0
Study 7822630 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rates of hyperactive/disruptive behaviors
Number of subjects: 0
Study 7822630 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral symptoms of both disorders
Number of subjects: 0
Study 3046638 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-n1 (Wellferon) intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months
Number of subjects: 66
Study 3046638 — intervention group
Group type: COMPARATOR
Intervention: Observation for six months
Number of subjects: 66
Study 31784704 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser (SML)
Number of subjects: 88
Study 31784704 — intervention group
Group type: COMPARATOR
Intervention: Threshold conventional laser (TCL)
Number of subjects: 88
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 30526678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (TNFi-naïve)
Number of subjects: 0
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (TNFi-naïve)
Number of subjects: 0
Study 30526678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TNFi-naïve)
Number of subjects: 0
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (TNFi-experienced)
Number of subjects: 0
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (TNFi-experienced)
Number of subjects: 0
Study 30526678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TNFi-experienced)
Number of subjects: 0
Study 30526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 28356129 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d probiotic
Number of subjects: 120
Study 28356129 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d synbiotic
Number of subjects: 120
Study 28356129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25767411 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib
Number of subjects: 105
Study 23650505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 198
Study 23650505 — intervention group
Group type: COMPARATOR
Intervention: Gardasil®
Number of subjects: 198
Study 23650505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix® and Gardasil®
Number of subjects: 198
Study 20587582 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent TSH-suppressive l-T4 substitution (low-TSH group)
Number of subjects: 25
Study 20587582 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of euthyroidism
Number of subjects: 25